Nebilet (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. At the same time it enhances nitric‑oxide release from the endothelium, causing vasodilation. The combined actions lower peripheral resistance and arterial pressure while supporting cardiac output in heart‑failure patients.

The dose of nebivolol is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate starting dose and any subsequent adjustments, following current clinical guidelines and local regulatory recommendations.

Safety data for nebivolol during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Nebilet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nebivolol is a highly selective β1‑blocker with additional nitric‑oxide‑mediated vasodilatory properties, which may result in fewer metabolic side effects compared with non‑selective beta‑blockers. Its dual mechanism can provide effective blood‑pressure control while preserving endothelial function, distinguishing it from older agents that lack vasodilatory activity.

Nebilet tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Nebilet is taken orally, usually with a glass of water. It can be taken with or without food, but the dose should be taken at the same time each day to maintain consistent blood levels. Patients should follow the prescriber’s instructions regarding timing and any dose‑adjustment steps.

Serious adverse events include marked bradycardia, severe hypotension, heart block, bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and allergic reactions such as rash, angioedema or anaphylaxis. Any of these symptoms require immediate medical evaluation.

Nebilet is contraindicated in patients with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block, decompensated heart failure, cardiogenic shock, or known hypersensitivity to nebivolol or any excipients. Caution is also advised for individuals with uncontrolled asthma, severe peripheral vascular disease, or significant hepatic impairment.